Buy Or Sell Opportunity • May 07
Now 23% overvalued Over the last 90 days, the stock has fallen 13% to CN¥36.95. The fair value is estimated to be CN¥30.15, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 9.8% over the last 3 years. Meanwhile, the company has become profitable. Revenue is forecast to grow by 53% in 2 years. Earnings are forecast to grow by 759% in the next 2 years. Reported Earnings • Apr 30
Full year 2025 earnings: EPS misses analyst expectations Full year 2025 results: EPS: CN¥0.09 (down from CN¥0.16 in FY 2024). Revenue: CN¥773.9m (up 3.2% from FY 2024). Net income: CN¥11.5m (down 46% from FY 2024). Profit margin: 1.5% (down from 2.8% in FY 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 64%. Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Medical Equipment industry in China. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 52 percentage points per year, which is a significant difference in performance. Announcement • Apr 30
Shanghai Aohua Photoelectricity Endoscope Co., Ltd., Annual General Meeting, May 22, 2026 Shanghai Aohua Photoelectricity Endoscope Co., Ltd., Annual General Meeting, May 22, 2026, at 14:00 China Standard Time. Location: 1F, No. 351, Pingbei Road, Minhang District, Shanghai China Buy Or Sell Opportunity • Apr 16
Now 20% overvalued Over the last 90 days, the stock has fallen 25% to CN¥34.91. The fair value is estimated to be CN¥29.04, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 13% over the last 3 years. Earnings per share has declined by 70%. Revenue is forecast to grow by 50% in 2 years. Earnings are forecast to grow by 1,196% in the next 2 years. Announcement • Mar 30
Shanghai Aohua Photoelectricity Endoscope Co., Ltd. to Report Q1, 2026 Results on Apr 30, 2026 Shanghai Aohua Photoelectricity Endoscope Co., Ltd. announced that they will report Q1, 2026 results on Apr 30, 2026 Reported Earnings • Mar 02
Full year 2025 earnings: EPS misses analyst expectations Full year 2025 results: EPS: CN¥0.09 (down from CN¥0.16 in FY 2024). Revenue: CN¥773.5m (up 3.2% from FY 2024). Net income: CN¥11.5m (down 46% from FY 2024). Profit margin: 1.5% (down from 2.8% in FY 2024). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 64%. Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Medical Equipment industry in China. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 56 percentage points per year, which is a significant difference in performance. Board Change • Jan 13
Less than half of directors are independent Following the recent departure of a director, there are only 4 independent directors on the board. The company's board is composed of: 4 independent directors. 5 non-independent directors. Independent Director Chao Lu was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Announcement • Dec 26
Shanghai Aohua Photoelectricity Endoscope Co., Ltd. to Report Fiscal Year 2025 Results on Apr 30, 2026 Shanghai Aohua Photoelectricity Endoscope Co., Ltd. announced that they will report fiscal year 2025 results on Apr 30, 2026 Reported Earnings • Oct 29
Third quarter 2025 earnings released: CN¥0.12 loss per share (vs CN¥0.27 profit in 3Q 2024) Third quarter 2025 results: CN¥0.12 loss per share (down from CN¥0.27 profit in 3Q 2024). Revenue: CN¥162.3m (up 10% from 3Q 2024). Net loss: CN¥15.3m (down 148% from profit in 3Q 2024). Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Medical Equipment industry in China. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 58 percentage points per year, which is a significant difference in performance. Announcement • Sep 30
Shanghai Aohua Photoelectricity Endoscope Co., Ltd. to Report Q3, 2025 Results on Oct 29, 2025 Shanghai Aohua Photoelectricity Endoscope Co., Ltd. announced that they will report Q3, 2025 results on Oct 29, 2025 Buy Or Sell Opportunity • Sep 24
Now 23% overvalued after recent price rise Over the last 90 days, the stock has risen 3.6% to CN¥48.00. The fair value is estimated to be CN¥39.02, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 21% over the last 3 years. Meanwhile, the company became loss making. Buy Or Sell Opportunity • Sep 05
Now 20% overvalued Over the last 90 days, the stock has fallen 15% to CN¥47.74. The fair value is estimated to be CN¥39.69, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 26% over the last 3 years. Meanwhile, the company became loss making. Announcement • Jun 30
Shanghai Aohua Photoelectricity Endoscope Co., Ltd. to Report First Half, 2025 Results on Aug 29, 2025 Shanghai Aohua Photoelectricity Endoscope Co., Ltd. announced that they will report first half, 2025 results on Aug 29, 2025 Buy Or Sell Opportunity • Jun 23
Now 23% overvalued after recent price rise Over the last 90 days, the stock has risen 13% to CN¥48.31. The fair value is estimated to be CN¥39.16, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 26% over the last 3 years. Meanwhile, the company became loss making. Declared Dividend • Jun 13
Dividend reduced to CN¥0.08 Dividend of CN¥0.08 is 73% lower than last year. Ex-date: 18th June 2025 Payment date: 18th June 2025 Dividend yield will be 0.2%, which is lower than the industry average of 2.2%. Buy Or Sell Opportunity • May 06
Now 25% overvalued after recent price rise Over the last 90 days, the stock has risen 18% to CN¥48.01. The fair value is estimated to be CN¥38.53, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 26% over the last 3 years. Meanwhile, the company became loss making. Major Estimate Revision • Apr 16
Consensus revenue estimates fall by 10% The consensus outlook for revenues in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from CN¥986.0m to CN¥882.9m. EPS estimate fell from CN¥0.945 to CN¥0.883 per share. Net income forecast to grow 395% next year vs 56% growth forecast for Medical Equipment industry in China. Consensus price target down from CN¥59.13 to CN¥57.37. Share price fell 4.1% to CN¥39.50 over the past week. Reported Earnings • Apr 11
Full year 2024 earnings: EPS and revenues miss analyst expectations Full year 2024 results: EPS: CN¥0.16 (down from CN¥0.43 in FY 2023). Revenue: CN¥749.5m (up 11% from FY 2023). Net income: CN¥21.0m (down 64% from FY 2023). Profit margin: 2.8% (down from 8.5% in FY 2023). Revenue missed analyst estimates by 11%. Earnings per share (EPS) also missed analyst estimates by 71%. Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Medical Equipment industry in China. Over the last 3 years on average, earnings per share has fallen by 20% per year but the company’s share price has only fallen by 3% per year, which means it has not declined as severely as earnings. Announcement • Apr 10
Shanghai Aohua Photoelectricity Endoscope Co., Ltd., Annual General Meeting, May 08, 2025 Shanghai Aohua Photoelectricity Endoscope Co., Ltd., Annual General Meeting, May 08, 2025, at 14:00 China Standard Time. Location: The Company's Meeting Room, Shanghai China Buy Or Sell Opportunity • Apr 07
Now 27% undervalued Over the last 90 days, the stock has risen 1.8% to CN¥40.72. The fair value is estimated to be CN¥55.61, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 29% over the last 3 years. Earnings per share has declined by 20%. Revenue is forecast to grow by 89% in 2 years. Earnings are forecast to grow by 879% in the next 2 years. Announcement • Mar 28
Shanghai Aohua Photoelectricity Endoscope Co., Ltd. to Report Q1, 2025 Results on Apr 18, 2025 Shanghai Aohua Photoelectricity Endoscope Co., Ltd. announced that they will report Q1, 2025 results on Apr 18, 2025 Reported Earnings • Feb 27
Full year 2024 earnings: EPS and revenues miss analyst expectations Full year 2024 results: EPS: CN¥0.16 (down from CN¥0.43 in FY 2023). Revenue: CN¥748.6m (up 10% from FY 2023). Net income: CN¥21.3m (down 63% from FY 2023). Profit margin: 2.8% (down from 8.5% in FY 2023). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 11%. Earnings per share (EPS) also missed analyst estimates by 71%. Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Medical Equipment industry in China. Over the last 3 years on average, earnings per share has fallen by 20% per year but the company’s share price has only fallen by 3% per year, which means it has not declined as severely as earnings. Buy Or Sell Opportunity • Feb 18
Now 22% undervalued after recent price drop Over the last 90 days, the stock has fallen 18% to CN¥42.35. The fair value is estimated to be CN¥54.54, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 31% over the last 3 years. Earnings per share has declined by 22%. Revenue is forecast to grow by 78% in 2 years. Earnings are forecast to grow by 283% in the next 2 years. Announcement • Jan 07
Shanghai Aohua Photoelectricity Endoscope Co., Ltd. (SHSE:688212) announces an Equity Buyback for CNY 200 million worth of its shares. Shanghai Aohua Photoelectricity Endoscope Co., Ltd. (SHSE:688212) announces a share repurchase program. Under the program, the company will repurchase up to CNY 200 million worth of its shares. The shares will be purchased at a price not exceeding CNY 45 per share. The repurchased shares will be used for employee stock ownership plan or equity incentive. If the repurchased shares are not transferred within 3 years after the announcement of the results of the share repurchase and the share change, the procedure for reducing the registered capital will be carried out in accordance with the law, the untransferred shares will be cancelled. The program will be funded from company's own funds and the special loan of CNY 180 million for stock repurchase provided by the Shanghai Branch of China CITIC Bank Corporation. The program will be valid for 12 months. Announcement • Dec 27
Shanghai Aohua Photoelectricity Endoscope Co., Ltd. to Report Fiscal Year 2024 Results on Apr 10, 2025 Shanghai Aohua Photoelectricity Endoscope Co., Ltd. announced that they will report fiscal year 2024 results on Apr 10, 2025 Major Estimate Revision • Oct 31
Consensus EPS estimates increase by 18%, revenue downgraded The consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast fell from CN¥968.8m to CN¥917.1m. EPS estimate rose from CN¥0.553 to CN¥0.651. Net income forecast to grow 169% next year vs 56% growth forecast for Medical Equipment industry in China. Consensus price target up from CN¥57.33 to CN¥59.29. Share price rose 3.3% to CN¥52.90 over the past week. Reported Earnings • Oct 25
Third quarter 2024 earnings released: EPS: CN¥0.27 (vs CN¥0.052 in 3Q 2023) Third quarter 2024 results: EPS: CN¥0.27 (up from CN¥0.052 in 3Q 2023). Revenue: CN¥147.0m (up 5.4% from 3Q 2023). Net income: CN¥31.6m (up 345% from 3Q 2023). Profit margin: 22% (up from 5.1% in 3Q 2023). The increase in margin was primarily driven by lower expenses. Revenue is forecast to grow 28% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Medical Equipment industry in China. Buy Or Sell Opportunity • Oct 23
Now 22% overvalued after recent price rise Over the last 90 days, the stock has risen 18% to CN¥52.07. The fair value is estimated to be CN¥42.64, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 31% over the last 3 years. Earnings per share has declined by 24%. Revenue is forecast to grow by 131% in 2 years. Earnings are forecast to grow by 718% in the next 2 years. Announcement • Sep 30
Shanghai Aohua Photoelectricity Endoscope Co., Ltd. to Report Q3, 2024 Results on Oct 25, 2024 Shanghai Aohua Photoelectricity Endoscope Co., Ltd. announced that they will report Q3, 2024 results on Oct 25, 2024 New Risk • Sep 25
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Chinese stocks, typically moving 8.5% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.5% average weekly change). Dividend is not well covered by earnings and cash flows. Payout ratio: 165% Paying a dividend despite having no free cash flows. High level of non-cash earnings (27% accrual ratio). Minor Risk Profit margins are more than 30% lower than last year (3.4% net profit margin). Buy Or Sell Opportunity • Sep 20
Now 25% undervalued after recent price drop Over the last 90 days, the stock has fallen 33% to CN¥32.00. The fair value is estimated to be CN¥42.41, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 31% over the last 3 years. Earnings per share has declined by 24%. Revenue is forecast to grow by 131% in 2 years. Earnings are forecast to grow by 718% in the next 2 years. Major Estimate Revision • Aug 29
Consensus EPS estimates fall by 18% The consensus outlook for earnings per share (EPS) in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from CN¥999.8m to CN¥979.9m. EPS estimate also fell from CN¥0.68 per share to CN¥0.56 per share. Net income forecast to grow 340% next year vs 42% growth forecast for Medical Equipment industry in China. Consensus price target down from CN¥71.08 to CN¥62.83. Share price fell 3.4% to CN¥39.14 over the past week. Price Target Changed • Aug 28
Price target decreased by 12% to CN¥62.83 Down from CN¥71.08, the current price target is an average from 4 analysts. New target price is 64% above last closing price of CN¥38.32. Stock is down 35% over the past year. The company is forecast to post earnings per share of CN¥0.56 for next year compared to CN¥0.43 last year. Reported Earnings • Aug 23
Second quarter 2024 earnings released: EPS: CN¥0.02 (vs CN¥0.17 in 2Q 2023) Second quarter 2024 results: EPS: CN¥0.02 (down from CN¥0.17 in 2Q 2023). Revenue: CN¥184.2m (up 13% from 2Q 2023). Net income: CN¥2.90m (down 87% from 2Q 2023). Profit margin: 1.6% (down from 13% in 2Q 2023). Revenue is forecast to grow 29% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Medical Equipment industry in China. Major Estimate Revision • Jul 29
Consensus EPS estimates fall by 11% The consensus outlook for fiscal year 2024 has been updated. 2024 EPS estimate fell from CN¥0.764 to CN¥0.68. Revenue forecast unchanged from CN¥999.8m at last update. Net income forecast to grow 166% next year vs 44% growth forecast for Medical Equipment industry in China. Consensus price target of CN¥71.08 unchanged from last update. Share price fell 12% to CN¥42.39 over the past week. New Risk • Jul 19
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 7.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (30% accrual ratio). Minor Risk Share price has been volatile over the past 3 months (7.3% average weekly change). Announcement • Jun 28
Shanghai Aohua Photoelectricity Endoscope Co., Ltd. to Report First Half, 2024 Results on Aug 23, 2024 Shanghai Aohua Photoelectricity Endoscope Co., Ltd. announced that they will report first half, 2024 results on Aug 23, 2024 Reported Earnings • Apr 30
First quarter 2024 earnings released: EPS: CN¥0.02 (vs CN¥0.12 in 1Q 2023) First quarter 2024 results: EPS: CN¥0.02 (down from CN¥0.12 in 1Q 2023). Revenue: CN¥169.3m (up 35% from 1Q 2023). Net income: CN¥2.76m (down 83% from 1Q 2023). Profit margin: 1.6% (down from 13% in 1Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 27% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Medical Equipment industry in China. Price Target Changed • Apr 27
Price target decreased by 7.2% to CN¥71.08 Down from CN¥76.60, the current price target is an average from 4 analysts. New target price is 28% above last closing price of CN¥55.40. Stock is down 14% over the past year. The company is forecast to post earnings per share of CN¥0.76 for next year compared to CN¥0.43 last year. Reported Earnings • Apr 14
Full year 2023 earnings: EPS misses analyst expectations Full year 2023 results: EPS: CN¥0.43 (up from CN¥0.16 in FY 2022). Revenue: CN¥678.1m (up 52% from FY 2022). Net income: CN¥57.9m (up 166% from FY 2022). Profit margin: 8.5% (up from 4.9% in FY 2022). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 27%. Revenue is forecast to grow 26% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Medical Equipment industry in China. Major Estimate Revision • Apr 12
Consensus EPS estimates fall by 15% The consensus outlook for fiscal year 2024 has been updated. 2024 EPS estimate fell from CN¥0.956 to CN¥0.817 per share. Revenue forecast steady at CN¥1.01b. Net income forecast to grow 94% next year vs 31% growth forecast for Medical Equipment industry in China. Consensus price target broadly unchanged at CN¥77.01. Share price fell 8.2% to CN¥54.38 over the past week. Announcement • Apr 10
Shanghai Aohua Photoelectricity Endoscope Co., Ltd., Annual General Meeting, May 07, 2024 Shanghai Aohua Photoelectricity Endoscope Co., Ltd., Annual General Meeting, May 07, 2024, at 14:00 China Standard Time. Location: The Company's Meeting Room, Shanghai China Announcement • Mar 29
Shanghai Aohua Photoelectricity Endoscope Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024 Shanghai Aohua Photoelectricity Endoscope Co., Ltd. announced that they will report Q1, 2024 results on Apr 30, 2024 Reported Earnings • Feb 27
Full year 2023 earnings: EPS misses analyst expectations Full year 2023 results: EPS: CN¥0.43 (up from CN¥0.16 in FY 2022). Revenue: CN¥678.1m (up 52% from FY 2022). Net income: CN¥58.0m (up 167% from FY 2022). Profit margin: 8.5% (up from 4.9% in FY 2022). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 27%. Revenue is forecast to grow 28% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Medical Equipment industry in China. Price Target Changed • Nov 06
Price target increased by 7.1% to CN¥77.40 Up from CN¥72.25, the current price target is an average from 5 analysts. New target price is 20% above last closing price of CN¥64.41. Stock is down 6.7% over the past year. The company is forecast to post earnings per share of CN¥0.65 for next year compared to CN¥0.16 last year. Reported Earnings • Oct 25
Third quarter 2023 earnings released: EPS: CN¥0.052 (vs CN¥0.02 in 3Q 2022) Third quarter 2023 results: EPS: CN¥0.052 (up from CN¥0.02 in 3Q 2022). Revenue: CN¥139.5m (up 23% from 3Q 2022). Net income: CN¥7.11m (up 102% from 3Q 2022). Profit margin: 5.1% (up from 3.1% in 3Q 2022). Revenue is forecast to grow 31% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Medical Equipment industry in China. Price Target Changed • Aug 25
Price target decreased by 12% to CN¥72.25 Down from CN¥82.05, the current price target is an average from 4 analysts. New target price is 32% above last closing price of CN¥54.83. Stock is up 16% over the past year. The company is forecast to post earnings per share of CN¥0.66 for next year compared to CN¥0.16 last year. New Risk • Aug 16
New major risk - Earnings quality The company has a high level of non-cash earnings. Accrual ratio: 37% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (37% accrual ratio). Minor Risk Profit margins are more than 30% lower than last year (9.7% net profit margin). Reported Earnings • Aug 06
Second quarter 2023 earnings released: EPS: CN¥0.17 (vs CN¥0.012 in 2Q 2022) Second quarter 2023 results: EPS: CN¥0.17 (up from CN¥0.012 in 2Q 2022). Revenue: CN¥163.6m (up 91% from 2Q 2022). Net income: CN¥21.5m (up CN¥19.9m from 2Q 2022). Profit margin: 13% (up from 1.9% in 2Q 2022). Revenue is forecast to grow 31% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Medical Equipment industry in China. Announcement • Jun 28
Shanghai Aohua Photoelectricity Endoscope Co., Ltd. to Report First Half, 2023 Results on Aug 15, 2023 Shanghai Aohua Photoelectricity Endoscope Co., Ltd. announced that they will report first half, 2023 results on Aug 15, 2023 Price Target Changed • May 03
Price target increased by 15% to CN¥79.57 Up from CN¥68.97, the current price target is an average from 2 analysts. New target price is 24% above last closing price of CN¥64.26. Stock is up 51% over the past year. The company is forecast to post earnings per share of CN¥0.75 for next year compared to CN¥0.16 last year. Reported Earnings • Apr 26
First quarter 2023 earnings released: EPS: CN¥0.12 (vs CN¥0.03 in 1Q 2022) First quarter 2023 results: EPS: CN¥0.12 (up from CN¥0.03 in 1Q 2022). Revenue: CN¥125.5m (up 54% from 1Q 2022). Net income: CN¥16.5m (up 386% from 1Q 2022). Profit margin: 13% (up from 4.2% in 1Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 33% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Medical Equipment industry in China. Reported Earnings • Feb 27
Full year 2022 earnings released: EPS: CN¥0.15 (vs CN¥0.55 in FY 2021) Full year 2022 results: EPS: CN¥0.15 (down from CN¥0.55 in FY 2021). Revenue: CN¥445.3m (up 28% from FY 2021). Net income: CN¥20.5m (down 64% from FY 2021). Profit margin: 4.6% (down from 16% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 31% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Medical Equipment industry in China. Board Change • Nov 16
Less than half of directors are independent There is 1 new director who has joined the board in the last 3 years. The new board member was an independent director. The company's board is composed of: 1 new director. 6 experienced directors. 3 highly experienced directors. 2 independent directors (7 non-independent directors). Independent Director Chao Lu was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Reported Earnings • Oct 25
Third quarter 2022 earnings released: EPS: CN¥0.02 (vs CN¥0.12 in 3Q 2021) Third quarter 2022 results: EPS: CN¥0.02 (down from CN¥0.12 in 3Q 2021). Revenue: CN¥113.4m (up 38% from 3Q 2021). Net income: CN¥3.51m (down 70% from 3Q 2021). Profit margin: 3.1% (down from 14% in 3Q 2021). Revenue is forecast to grow 35% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Medical Equipment industry in China. Reported Earnings • Aug 26
Second quarter 2022 earnings released: EPS: CN¥0.012 (vs CN¥0.002 loss in 2Q 2021) Second quarter 2022 results: EPS: CN¥0.012 (up from CN¥0.002 loss in 2Q 2021). Revenue: CN¥85.7m (up 14% from 2Q 2021). Net income: CN¥1.66m (up CN¥1.91m from 2Q 2021). Profit margin: 1.9% (up from net loss in 2Q 2021). Over the next year, revenue is forecast to grow 56%, compared to a 26% growth forecast for the Medical Equipment industry in China. Buying Opportunity • Jun 23
Now 20% undervalued Over the last 90 days, the stock is up 16%. The fair value is estimated to be CN¥66.27, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 24% over the last year. Earnings per share has grown by 29%. Revenue is forecast to grow by 45% in a year. Earnings is forecast to grow by 33% in the next year. Reported Earnings • Apr 27
First quarter 2022 earnings: EPS exceeds analyst expectations First quarter 2022 results: EPS: CN¥0.03 (down from CN¥0.09 in 1Q 2021). Revenue: CN¥81.6m (up 14% from 1Q 2021). Net income: CN¥3.41m (down 64% from 1Q 2021). Profit margin: 4.2% (down from 13% in 1Q 2021). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 53%. Over the next year, revenue is forecast to grow 42%, compared to a 25% growth forecast for the industry in China. Board Change • Apr 27
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Reported Earnings • Feb 24
Full year 2021 earnings: EPS exceeds analyst expectations Full year 2021 results: EPS: CN¥0.56 (up from CN¥0.18 in FY 2020). Revenue: CN¥347.1m (up 32% from FY 2020). Net income: CN¥57.6m (up 211% from FY 2020). Profit margin: 17% (up from 7.0% in FY 2020). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 56%. Over the next year, revenue is forecast to grow 29%, compared to a 24% growth forecast for the industry in China.